Glucoraphanin Composition Stability Using Basic Salt

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Compositions comprising glucoraphanin and myrosinase face stability issues during storage, leading to decreased glucoraphanin content, discoloration, and an unpleasant bitter taste, affecting the quality and efficacy of products intended to convert glucoraphanin into sulforaphane.

Innovation Solution

Incorporating a basic salt compound into the composition of glucoraphanin and myrosinase improves stability, maintaining appearance and taste while ensuring effective conversion to sulforaphane, with the composition being in a solid form such as powder, granules, or tablets.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If glucoraphanin and myrosinase are stored together in a composition, then sulforaphane can be converted and produced, but the composition becomes unstable during storage leading to degradation

Engineering Contradiction:
Improvestability of glucoraphanin-myrosinase compositionVSAvoidstability of glucoraphanin content
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The composition is segmented into two separate components: glucoraphanin and myrosinase, which are stored separately to prevent premature reaction and degradation. This segmentation maintains stability during storage while enabling sulforaphane conversion when the components are combined at the point of use.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

An intermediary substance or system is introduced to control and regulate the interaction between glucoraphanin and myrosinase during storage and conversion, preventing unwanted degradation while facilitating controlled sulforaphane production when needed.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Quantity of substance

If glucoraphanin is converted to sulforaphane during storage, then active anti-cancer compound is produced, but the composition discolors and develops bitter taste

Engineering Contradiction:
Improvesulforaphane production rateVSAvoiddiscoloration and bitter taste
Core Design Contradiction:
Quantity of substanceVSObject-generated harmful factors

Solution Approach 1:

The composition is prepared in advance with all necessary components (glucoraphanin and myrosinase) in a stable, inactive state during storage. The conversion to sulforaphane is triggered by a preliminary action at the point of use, such as adding water or a specific trigger, ensuring that the active compound is produced only when needed and not during storage, thereby preventing discoloration and bitter taste development.

Inventive Principle:
Principle #10Preliminary action

3Stability of the object's composition

If glucoraphanin and myrosinase are mixed in solid form, then the composition is stable for storage, but conversion to sulforaphane is insufficient without water

Engineering Contradiction:
Improvestorage stabilityVSAvoidsulforaphane conversion efficiency
Core Design Contradiction:
Stability of the object's compositionVSProductivity

Solution Approach 1:

The composition transitions from a static, stable solid form during storage to a dynamic, reactive state when water or a triggering substance is added. This dynamic transition enables the glucoraphanin-myrosinase reaction to proceed efficiently, converting to sulforaphane when needed while maintaining stability during storage.

Inventive Principle:
Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The addition of a basic salt compound enhances the stability of the glucoraphanin-myrosinase composition, maintaining sulforaphane production rates and product quality even after accelerated stability testing, preventing degradation and maintaining flavor.

Implementation Method 1

myrosinase can decompose glucoraphanin to produce products including biologically active isothiocyanates

Methodology Applied
Scientific EffectEnzymatic hydrolysis: Hydrolysis

Implementation Method 2

component II providing myrosinase

Methodology Applied
Scientific EffectEnzyme: Enzyme

Implementation Method 3

The composition according to any of claims 1-5, wherein the basic salt compound increases a pH of the composition to 6.5-8.5

Methodology Applied
Scientific EffectpH buffering:

Data Source

PatentUS20220193100A1Composition containing glucoraphanin and use thereof
Publication Date: 2022.06.23 SHENZHEN F&S BIO TECH CO LTD

AI summary

The present disclosure relates to a composition comprising glucoraphanin and its therapeutic use.